Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Genus Pharmaceuticals Limited, T/A Genus Pharmaceuticals, Linthwaite, Huddersfield, HD7 5QH, UK
Pharmacotherapeutic group: Cytostatic agent from the group of vinca alkaloids; mitosis inhibitor
ATC code: L01CA03
Vindesine sulphate is an antineoplastic agent derived from vinblastine, like the other vinca alkaloids it causes mitotic arrest in metaphase by binding to microtubular protein.
The pharmacokinetics of vindesine is similar to those of the other vinca alkaloids. After intravenous administration, elimination from the blood is triphasic, and the drug is rapidly distributed to body tissues. It is metabolised primarily in the liver and excreted in bile and urine.
Animal studies with vindesine suggest that teratogenic effects may occur.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
